Sodium Carbonate → 5-{8-[6-(4-Isopropyl-piperazin-1-yl)-pyridin-3-ylamino]-imidazo[1,2-a]pyrazin-5-yl}-2,3-dihydro-isoindol-1-one

HRID 1366212

Reaktionsgleichung

Reaktionsgleichung von HRID 1366212
[N:1]1(C2C=[CH:11][C:10]([NH:13][C:14]3[C:15]4[N:16]([CH:30]=[CH:31][N:32]=4)[C:17]([C:20]4[CH:21]=[C:22]5[C:26](=[CH:27][CH:28]=4)[C:25](=[O:29])[NH:24][CH2:23]5)=[CH:18][N:19]=3)=[CH:9][CH:8]=2)CCOCC1.BrC1N2C=CN=C2C(NC2C=[N:46][C:47]([N:50]3[CH2:55][CH2:54][N:53]([CH:56]([CH3:58])[CH3:57])[CH2:52][CH2:51]3)=CC=2)=NC=1.CC1(C)C(C)(C)OB(C2C=C3C(=CC=2)C(=O)NC3)O1.C([O-])([O-])=O.[Na+].[Na+]>O1CCOCC1.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[NH3:1].[CH:56]([N:53]1[CH2:52][CH2:51][N:50]([C:47]2[N:46]=[CH:11][C:10]([NH:13][C:14]3[C:15]4[N:16]([CH:30]=[CH:31][N:32]=4)[C:17]([C:20]4[CH:21]=[C:22]5[C:26](=[CH:27][CH:28]=4)[C:25](=[O:29])[NH:24][CH2:23]5)=[CH:18][N:19]=3)=[CH:9][CH:8]=2)[CH2:55][CH2:54]1)([CH3:58])[CH3:57]

Komponenten

8

Edukt 4

HCID 10340Sodium CarbonateHCID 219557955-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-oneHCID 573939935-[8-(4-Morpholin-4-yl-phenylamino)-imidazo[1,2-a]pyrazin-5-yl]-2,3-dihydro-isoindol-1-oneHCID 59023102(5-Bromo-imidazo[1,2-a]pyrazin-8-yl)-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amine

Produkt 2

HCID 222AmmoniaHCID 590230745-{8-[6-(4-Isopropyl-piperazin-1-yl)-pyridin-3-ylamino]-imidazo[1,2-a]pyrazin-5-yl}-2,3-dihydro-isoindol-1-oneAusbeute 50 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 178418397HCID 178418397, VerbindungKatalysatorHCID 312751,4-DioxaneLösungsmittel

Versuchsvorschrift

In the same way as described for Compound 178, step 4, using (5-bromo-imidazo[1,2-a]pyrazin-8-yl)-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amine (0.05 g, 0.12 mmol), 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-isoindol-1-one (0.056 g, 0.22 mmol), 1.5M Na2CO3 (0.64 mL, 0.96 mmol) and Pd(PPh3)4 (0.042 g, 0.36 mmol) in dioxane (2 mL). Purification using silica gel column chromatography, eluting with DCM followed by 99:1 and 97:3 DCM:NH3 (7M in MeOH), affords the title compound as a yellow solid (28 mg, 50%). Conversion into the mesylate salt, as described for Compound 178, step 4, affords the title compound as a yellow solid (32 mg, 95%). LCMS: Rt 2.70 min (92%); m/z (APCI) 469 (M+H)+; 1H-NMR (400 MHz, d6-DMSO) δ (ppm) 1.34 (6H, d), 2.34 (3H, s, MsOH), 3.10-3.21 (4H, m), 3.57-3.59 (3H, m), 4.43 (2H, d), 4.52 (2H, s), 7.08 (1H, d), 7.52 (1H, s), 7.77-7.94 (4H, m), 8.07 (1H, s), 8.30 (1H, d), 8.75 (1H, s), 8.83 (1H, br s), 9.34 (1H, br s), 9.88 (1H, br s).

Aufarbeitung

  1. customPurification
  2. washeluting with DCM

Quellen und Nachweise

ORD-Eintrag
ord-b038d27a9ee14739b22e941971e34e8a
Quelldatensatz
uspto-grants-2011_02
Patentnummer
US07893058B2

Verknüpfte Notizen

Wird geladen…